4//SEC Filing
Kutok Jeffery 4
Accession 0000899243-22-028417
CIK 0001571498other
Filed
Aug 10, 8:00 PM ET
Accepted
Aug 11, 8:52 PM ET
Size
9.1 KB
Accession
0000899243-22-028417
Insider Transaction Report
Form 4
Epizyme, Inc.EPZM
Kutok Jeffery
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock, par value $0.0001
2022-08-09$1.39/sh+380,000$528,200→ 474,563 total - Tax Payment
Common Stock, par value $0.0001
2022-08-09$1.39/sh−354,496$492,749→ 120,067 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-08-09−380,000→ 0 totalExercise: $1.39Exp: 2032-03-16→ Common Stock (380,000 underlying)
Footnotes (2)
- [F1]These shares were withheld so the Reporting Person could satisfy the exercise price arising from a net (cashless) exercise of stock options that occurred on August 9, 2022.
- [F2]On June 27, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. Pursuant to the terms of the Merger Agreement, each Exercisable Pre-Close Option (as defined in the Merger Agreement) became exercisable on the Acceleration Date (August 5, 2022) up to and through the close of regular trading on the Nasdaq Stock Market on the second (2nd) business day thereafter (August 9, 2022).
Documents
Issuer
Epizyme, Inc.
CIK 0001571498
Entity typeother
Related Parties
1- filerCIK 0001697644
Filing Metadata
- Form type
- 4
- Filed
- Aug 10, 8:00 PM ET
- Accepted
- Aug 11, 8:52 PM ET
- Size
- 9.1 KB